Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing

Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing

PHILADELPHIA, Dec. 3, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive.

Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases.

The complaint asserts that, throughout the Class Period, Defendants failed to disclose that: (i) the efficacy of nimacimab, Skye's lead product candidate, was lower than what had been represented to investors; and (ii) as a result, the drug's clinical and commercial potential had been overstated.

On October 6, 2025, Skye issued a press release announcing topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, disclosing that that the primary endpoint of 8% difference in weight loss compared to placebo had not been met. Following these disclosures, Skye's stock price declined $2.85 per share, or 60%, closing at $1.90 on October 6, 2025.

If you are a Skye investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:
Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com

Caitlin Adorni
Director of Portfolio & Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
cadorni@bergermontague.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigating-claims-on-behalf-of-skye-bioscience-inc-nasdaq-skye-investors-after-class-action-filing-302632414.html

SOURCE Berger Montague